Dr. Olderman to Highlight Antimicrobial Protection in
Textiles Applications at Orlando Conference
GAINESVILLE, Florida, December 4, 2007 - Quick-Med Technologies announced today that its Vice President of Research & Development and Commercialization, Gerald M. Olderman, Ph.D., will present "Unique and New: A Bonded Antimicrobial Concept," at the Summit Session on Antimicrobials in Plastic and Textile Applications Conference on December 10, 2007 at the Royal Plaza Hotel in Orlando, Fla.
The added value that antimicrobial properties contribute to consumer goods and medical devices made with plastics and textiles is powerfully evident in the marketplace today. Strains of common bacteria are becoming increasingly resistant to traditional antibiotics, driving a need for more advanced preventative products in hospitals and around the house. Bacterial contamination is not the only cause for concern - microbes such as mold, mildew and other fungi are the cause of foul odors and along with viruses are risks to health as well.
Dr. Olderman's presentation will showcase features and benefits of NIMBUSŪ antimicrobial technology in plastic and textile applications. It will emphasize the uniqueness of a bonded antimicrobial, the resulting extraordinary performance of NIMBUSŪ, its effectiveness against resistant bacteria such as MRSA and VRE, its versatility in customizing substrate design to end use requirements and its cost effectiveness. The need for a universally accepted test method that simulates end use parameters will be emphasized as well.
The Intertech-Pira conference, Antimicrobials in Plastic and Textile Applications (Click here: Antimicrobials in Plastic and Textile Applications - IntertechPira), will reveal how the latest innovations in nano antimicrobials can do everything from reduce harmful gasses and reduce odors to increase the shelf life of products and provide self cleaning functionality for the ever increasing consumer demands.
To schedule a meeting with Dr. Olderman, please contact us at (888) 835-2211 Ext 107 or email to nsorobey@quickmedtech.com
About Dr. Gerald M. Olderman
Dr. Olderman is the Vice President of Research & Development and Commercialization of Quick-Med Technologies, and a member of the Company's Board of Directors. Dr. Olderman has over 35 years in the healthcare industry including 31 years in technical management of product development teams, and 25 years as head of research and development for major product divisions of three fortune 500 companies. As Vice President of Research & Development and Commericialization, Dr. Olderman is responsible for NIMBUSŪ strategic planning and direction of the research & development. Prior to joining Quick-Med Technologies, Dr. Olderman served as Director and Head of Research and Development for C.R. Bard, Inc.'s Cardiopulmonary Division, where he organized a new product development process in which 19 new medical devices were developed. Dr. Olderman also served as Vice President for Domestic and International Research and Development for the Pharmseal Division of Baxter Healthcare Corp. and Vice President for Research and Development for Converters, a division of American Hospital Supply Corporation prior to its acquisition by Baxter Healthcare Corporation. Dr. Olderman held management positions for Johnson and Johnson during his tenure from 1961-1978 including election to the board of directors of Surgikos as Vice President of Research & Development in 1975. Dr. Olderman received a B.S in Chemistry from Rensselaer Polytechnic Institute in New York. He also holds an M.S. and Ph.D. in Physical Chemistry from Seton Hall University in New Jersey.
About NIMBUSŪ
The Company's patented technology, NIMBUSŪ (Novel Instrinsically Microbonded Utility Substrate), employs a family of advanced antimicrobial polymers that destroy bacteria at the cellular level, thereby eliminating the risk of developing drug resistance. Unlike any other microbicide on the market today, the NIMBUSŪ technology works by creating a permanent bond with a multitude of substrates (without leaching) and is less than 10% the cost of silver-based antimicrobials. Studies conducted by the Company, as well as by independent laboratories, demonstrate that NIMBUSŪ is highly effective, including against methicillin-resistant Staphylococcus aureus ("MRSA") and vancomycin-resistant Enterococcus ("VRE"), two of the most significant antibiotic-resistant organisms responsible for hospital-acquired and community-acquired infections.
